Kazakh Neurobiologist Leads Groundbreaking Study on Blindness Treatment Published in Nature

A research team led by 27-year-old Kazakh neurobiologist Temurkhan Ayupov, a doctoral candidate at the University of Basel (Switzerland), has introduced a revolutionary method for treating neurodegenerative diseases such as glaucoma and Parkinson’s. The study, published in the prestigious journal Nature, unveils a targeted approach to cellular restoration that could transform the future of clinical medicine.

The research focuses on mitochondria—the primary energy source for cells. In conditions like glaucoma and Parkinson’s, nerve cells and retinal axons suffer from an energy deficit due to mitochondrial damage, leading to gradual cell death.

Ayupov and his team developed "MitoCatch," a technology colloquially referred to as a "mitochondrial GPS system." Unlike previous donor transplantation methods that suffered from low efficiency, this new technology utilizes specific protein markers on the surface of donor mitochondria. These molecules bind to receptors on damaged cells, ensuring the mitochondria are delivered with pinpoint accuracy. Once the connection is established, the cell absorbs the healthy mitochondria, utilizing them as a fresh power source.

The six-year study involved a collaborative effort from 29 scientists across 17 countries, conducting over 50 additional experiments. Tests were performed on laboratory mice and neurons from patients suffering from Leber’s hereditary optic neuropathy. The results demonstrated a delivery precision increase of over 1,000%, with neuron viability improving by 23.6% in human cells and 40% in mice. Currently, a biotechnological startup is being established based on this project.

The team aims to secure $20 million in investment to initiate clinical trials and transition the technology into practical medical use. This publication in Nature serves as international validation, positioning MitoCatch as a potential gold standard for treating blindness and severe neurological disorders.